Navigation Links
Onyx Pharmaceuticals Reports First Quarter 2011 Financial Results
Date:5/4/2011

SOUTH SAN FRANCISCO, Calif., May 4, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today reported its financial results for the first quarter 2011. Onyx reported a non-GAAP net loss of $14.2 million, or $0.23 per diluted share, for the first quarter 2011 compared to a non-GAAP net loss of $1.5 million, or $0.02 per diluted share, for the same period in 2010. Non-GAAP net loss excludes, among other items, adjustments to contingent consideration expense in connection with Onyx's acquisition of Proteolix Inc., or Proteolix; employee stock-based compensation expense; non-cash imputed interest expense related to the application of Accounting Standards Codification ("ASC") 470-20 and charges associated with the restructuring of Onyx's development, collaboration, option and license agreement with S*BIO Pte Ltd., or S*BIO.

"2011 is a pivotal year of execution and growth for Onyx as we prepare to deliver a number of significant near-term milestones," said N. Anthony Coles, M.D., president and chief executive officer of Onyx. "The NDA for carfilzomib in relapsed and refractory multiple myeloma is on track for filing; our Phase 3 confirmatory trials, ASPIRE and FOCUS, are enrolling patients; and ONX 0912, our next generation proteasome inhibitor, is expected to advance to Phase 2. Importantly, we are ramping up our preparation for the commercialization of carfilzomib, in anticipation of a potential U.S. launch next year."

On a GAAP basis, Onyx reported a net loss of $49.2 million, or $0.78 per diluted share, for the first quarter 2011 compared to a net loss of $12.0 million, or $0.19 per diluted share, for the same period in 2010. A description of the non-GAAP calculations and reconciliation to comparable GAAP measures is provided in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Loss."

Revenue from Collaboration Agreement
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Relmada Therapeutics, Inc., ... the treatment of chronic pain, announced today that it ... the position of  Senior Director of Clinical Development. ... James has established and led successful global clinical operations ... , to facilitate the clinical development of numerous therapeutics ...
(Date:9/18/2014)... , Sept. 18, 2014 /CNW/ - A new expert panel ... Canada , released today by the Council ... and effective medicines for children. Each year about half ... use at least one prescription drug. Much of this ... the authorized use), creating potential health risks. ...
(Date:9/18/2014)... MARLBOROUGH, Mass. , Sept. 18, 2014 ... RXII ), a biotechnology company focused on ... major unmet medical needs using RNA-targeted technologies, ... Executive Officer, Dr. Geert Cauwenbergh , ... Annual BioPharm America™ Conference on Wednesday, September ...
Breaking Medicine Technology:Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
... of evaluable heavily-pretreated patients in the high dose ... tolerated overall.DALLAS, March 5 ACCESS PHARMACEUTICALS, ... safety and efficacy results from its Phase 2 ... heavily pretreated ovarian cancer patients. In this monotherapy ...
... March 4 A new study by researchers at ... essential B vitamins, including B6, B12, and folic acid, ... of the leading causes of vision loss among older ... key omega-3 fatty acids and phytosterols, are also contained ...
Cached Medicine Technology:Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 2Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 3Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 4Harvard Study Shows Folic Acid, B Vitamins in Animi-3(R) May Prevent Vision Loss 2
(Date:9/18/2014)... has proven it true: exercise is good for you. ... that exercise may have an added benefit for cancer ... mouse model of melanoma, found that combining exercise with ... Joseph Libonati, an associate professor in the School of ... Translational Nursing Research, was the senior author on the ...
(Date:9/18/2014)... 18, 2014 TayganPoint Consulting Group, ... that President and co-founder John Cassimatis was named ... Winners for 2014, recognizing the region’s top healthcare ... emerging executive of the year. , The Innovation ... sciences that continue to shape the medical industry ...
(Date:9/18/2014)... 2014 Ben Quirk, CEO of Quirk ... Leadership Award by the Savannah Science Seminar in recognition ... throughout the nation and especially in Savannah. , “I ... Ben. “The Savannah Science Seminar is an amazing program ... generations have gone through the program,” he added. Eleventh ...
(Date:9/18/2014)... developed a new method to study Ebola virus in ... Conservation Society (WCS)-led research, published today in the journal ... of fecal samples from wild great apes to identify ... This represents a new tool for performing large, population-scale ... virus is studied and improve our understanding of the ...
(Date:9/18/2014)... The National Institutes of Health (NIH) recently awarded ... million grant to the Los Angeles Biomedical Research Institute ... of a vaccine to protect patients from the healthcare-related ... (MRSA). , The National Institute of Allergy ... grant to LA BioMed infectious disease specialists John E. ...
Breaking Medicine News(10 mins):Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... NY -- Vivian W. Pinn, MD will be awarded ... the 20th Annual Congress on Women,s Health, March 16-18, ... providers from across the country will gather at the ... advances in diagnosis and management, and innovative translational research ...
... rare in the United States but the third-leading cause of ... infections like chronic hepatitis, but the link is poorly understood. ... mechanism in mice that triggers inflammation in the liver and ... demonstrated in a mouse model that a particular micro-RNA (miR-124) ...
... , FRIDAY, Dec. 9 (HealthDay News) -- Depression and ... intensive care unit after treatment for a potentially deadly condition ... findings may also apply to ICU patients with other types ... machines, according to the researchers. "When people are discharged ...
... cells in the blood appears to have no relationship to ... breast cancer, according to new research from Fox Chase Cancer ... cells may signal that the disease has spread to other ... The results will be presented on Friday, December 9 ...
... DEC. 9, 2011] The investigation of a 2009 multistate ... an important cause of bacterial gastrointestinal illness, led to ... in Clinical Infectious Diseases and available ... recommendations for prevention, including a stronger message for consumers: ...
... Children who suffer from persistent or recurring chronic pain ... risk of developing internalizing symptoms such as anxiety, in response ... chronic pain in children and adolescents in 20 years, a ... from chronic pain and that girls suffer more frequently from ...
Cached Medicine News:Health News:Dr. Vivian W. Pinn to receive inaugural Bernadine Healy Award 2Health News:Researchers identify a novel therapeutic approach for liver cancer 2Health News:Depression, Disability Can Follow ICU Care: Study 2Health News:Circulating tumor cells not linked to survival in newly diagnosed inflammatory breast cancer 2Health News:Circulating tumor cells not linked to survival in newly diagnosed inflammatory breast cancer 3Health News:Ready-to-bake cookie dough not ready-to-eat, study of E. coli outbreak finds 2Health News:Chronic pain in children and adolescents becoming more common 2
Large image and wide angle design for transurethral examination and treatment of the ureter and renal pelvis....
High intensity lamp with built-in, switchable spare lamp. Low-noise fan with reduced air turbulence....
Calculate accurate growth percentiles and Z scores using the latest CDC growth charts....
PDA-version of the leading portable drug reference....
Medicine Products: